Pharsight

Drugs that contain Glycopyrrolate; Neostigmine Methylsulfate

1. Prevduo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110054 AZURITY Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

US11938217 AZURITY Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

US10456354 AZURITY Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

Market Authorisation Date: 23 February, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PREVDUO family patents

Family Patents